Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
Eligible for screening study DCP 001
S1703 will be closed to accrual to Step 1 (Registration), effective August 15, 2026.
